Early rise of glutamate-glutamine levels in mild cognitive impairment: Evidence for emerging excitotoxicity.
J Neuroradiol
; 51(2): 168-175, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-37777087
ABSTRACT
BACKGROUND:
Use proton magnetic resonance spectroscopy (1H-MRS) non invasive technique to assess the modifications of glutamate-glutamine (Glx) and gammaaminobutyric acid (GABA) brain levels in patients reporting a cognitive complainMETHODS:
Posterior cingular cortex 1H-MRS spectra of 46 patients (19 male, 27 female) aged 57 to 87 years (mean 73.32 ± 7.33 years) with a cognitive complaint were examined with a MEGA PRESS sequence at 3T, and compounds Glutamateglutamine (Glx), GABA, Creatine (Cr) and NAA were measured. From this data the metabolite ratios Glx/Cr, GABA/Cr and NAA/Cr were calculated. In addition, all patient performed the Mini Mental State Evaluation (MMSE) and 2 groups were realized with the clinical threshold of 24.RESULTS:
16 patients with MMSE ã 24 and 30 patients with MMSE ã 24. Significant increase of Glx/Cr in PCC of patients with MMSE ã 24 compared to patients with MMSE ã 24. Moreover, GABA/Cr ratio exhibited a trend for a decrease in PCC between the two groups, while they showed a significant decrease NAA/Cr ratio.CONCLUSION:
Our results concerning Glx are in agreement with a physiopathological hypothesis involving a biphasic variation of glutamate levels associated with excitotoxicity, correlated with the clinical evolution of the disease. These observations suggest that MRS assessment of glutamate levels could be helpful for both diagnosis and classification of cognitive impairment in stage.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Disfunção Cognitiva
/
Glutamina
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Neuroradiol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
França